Profusa Revenue and Competitors

Location

$80.9M

Total Funding

Estimated Revenue & Valuation

  • Profusa's estimated annual revenue is currently $8.3M per year.(i)
  • Profusa received $45.0M in venture funding in August 2018.
  • Profusa's estimated revenue per employee is $125,500
  • Profusa's total funding is $80.9M.

Employee Data

  • Profusa has 66 Employees.(i)
  • Profusa grew their employee count by -3% last year.

Profusa's People

NameTitleEmail/Phone
1
VP Software and Data ScienceReveal Email/Phone
2
Head, Government BusinessReveal Email/Phone
3
Head Digital Health BusinessReveal Email/Phone
4
Director QualityReveal Email/Phone
5
Co-founder, President & Chief Scientific OfficerReveal Email/Phone
6
Co-Founder, President & Chief Scientific OfficerReveal Email/Phone
7
Product ManagerReveal Email/Phone
8
Program Manager, Government ProjectsReveal Email/Phone
9
Chairman & CEOReveal Email/Phone
10
Electrical EngineerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$20.3M817%N/AN/A
#2
$8.5M346%N/AN/A
#3
$4.5M18-10%N/AN/A
#4
$8M32-6%N/AN/A
#5
$5.3M210%N/AN/A
#6
$54.2M2169%N/AN/A
#7
$12M48N/AN/AN/A
#8
$10M405%N/AN/A
#9
$30.1M12022%N/AN/A
#10
$14.1M562%N/AN/A
Add Company

What Is Profusa?

Profusa's mission is to make our body's chemistry easily accessible to improve health and wellness. We are dedicated to becoming a leader in the development of real-time biosensors that provide unprecedented insights into our overall health status. We are leading the development of a new generation of biointegrated sensors that empowers the individual with the ability to monitor their unique body chemistry in unprecedented ways to transform the management of personal health and disease. Our technology enables the development of bioengineered sensors that become one with the body to detect and continuously transmit actionable, medical-grade data for personal and medical use. Profusa's first clinical offering, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. It may be used in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds (diabetic ulcers, pressure sores) that do not heal properly; and reconstructive surgery. Any questions Please visit profusa.com or email us at info@profusa.com

keywords:Biotechnology,Healthcare,Medical Devices,Medical Diagnostics

$80.9M

Total Funding

66

Number of Employees

$8.3M

Revenue (est)

-3%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Profusa News

2022-04-19 - Profusa compra el hotel Arco de San Juan de Murcia

Profusa compra el hotel Arco de San Juan de Murcia. La compañía de desarrollos inmobiliarios del Grupo Fuertes realizará una remodelación y...

2022-04-19 - Profusa adquiere el Hotel Arco de San Juan de 4 estrellas

Quiere impulsar el desarrollo turístico de la Región de Murcia. La compañía de desarrollos inmobiliarios realizará una remodelación y tiene...

2022-04-19 - Profusa (Grupo Fuertes) adquiere el Hotel Arco de San Juan de 4 estrellas para impulsar el desarrollo turístic

Profusa (Grupo Fuertes) adquiere el Hotel Arco de San Juan de 4 estrellas para impulsar el desarrollo turístico de la Región de Murcia.

2019-08-08 - Profusa and Partners Receive DARPA Award to Speed ...

SOUTH SAN FRANCISCO, Calif., Aug. 8, 2019 /PRNewswire/ -- Profusa, an empowered health company that is pioneering the next generation ...

2019-04-11 - Profusa Expands Leadership Team with Digital Health ...

Prior to joining Profusa, Icke led the Digital Health Business Unit at Becton Dickinson (BD), where he focused on consumer-centric digital ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$24M66-4%$1.3B
#2
$5.1M6610%$316M
#3
$9.3M693%N/A
#4
$17.6M706%N/A
#5
$15M720%N/A

Profusa Funding

DateAmountRoundLead InvestorsReference
2015-12-17$13.2MB3E BioventuresArticle
2018-08-15$45.0MCVMS Investment GroupArticle